VivaVision Announces That VVN539 Has Been Formally Submitted for U.S. Phase II Clinical Trial Application


VivaVision, an innovative ophthalmic drug company which invested and incubated by Viva BioInnovator, announced that it has submitted a Phase II clinical trial application for the new drug VVN539 for the treatment of open-angle glaucoma to the FDA on May 5, 2022, and will start the clinical study in June 2022.

VVN539 is a new generation, dual-targeted IOP-lowering drug that acts on the trabecular meshwork of the eye to increase the outflow of aqueous humor, thereby reducing IOP. In preclinical animal models, VVN539 has shown excellent IOP-lowering efficacy.

About VivaVivion Biotech

VivaVision is a clinical stage pharmaceutical company focused on best-in-class and first-in-class therapies for ocular diseases. Besides VVN001 program, VivaVision is developing VVN539 for the treatment for Glaucoma or Ocular Hypertension, and VVN461 for the treatment of non-infectious ocular inflammation of Uveitis. VivaVision is also engaged in discovery and development of novel therapies for the treatment of other anterior and posterior eye diseases. For more info, visit www.vivavisionbio.com.